BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

Treating patients with a drug before surgery greatly reduced the chances of the cancer coming back, a small trial found.

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Around one in 400 people carry mutations in either the BRCA1 or BRCA2 genes. Cancer Research ... being able to repair their DNA by blocking a protein called PARP, which causes the cancerous ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...

When former President Joe Biden revealed he had been diagnosed with prostate cancer earlier this year, it reignited a ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...